Auger

Quick links to important sections

Auger

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Auger

What is Auger? (Co-amoxiclav)

Property Description
Active Ingredients Amoxicillin, Clavulanic Acid
Drug Type Fixed-dose combination product
Pharmacological Class Potentiated penicillin (Beta-Lactam antibiotic)
Common Use Treatment of bacterial infections
Origin Semi-synthetic (derived from natural sources)

Identity and Classification

Auger is a prescription-only medicine medically known as Co-amoxiclav, classified as an antibacterial agent and a potentiated penicillin used to fight bacterial infections. This drug belongs to the established Beta-Lactam antibiotic family and is designed as a fixed-dose combination product, containing two distinct active ingredients (Amoxicillin and Clavulanic Acid) combined into a single preparation. The drug is characterized as an important antibacterial agent for the general patient population. This formulation is semi-synthetic in origin, available in various dosage forms, including tablets and oral suspensions.


Composition and General Purpose

Auger is composed of the antibiotic Amoxicillin and the protecting ingredient Clavulanic Acid. Amoxicillin provides the core bactericidal action by destroying the bacterial cell wall. Clavulanic Acid serves as a Beta-lactamase inhibitor, which is crucial because it shields the Amoxicillin from defensive enzymes that resistant bacteria produce.

This creates a necessary synergistic effect that provides a broad-spectrum antibiotic capability. The general purpose of this combination is to fight bacterial infections, particularly those caused by microorganisms that have developed antimicrobial resistance to single-agent penicillins. This ensures the medicine remains effective in treating the underlying infectious diseases.

Regulatory References

  1. FDA Label (via DailyMed)

What side effects are possible with Auger?

Possible Side Effects and Safety Information

The safety profile of Auger (Co-amoxiclav) is formally classified based on frequency and the physiological systems affected, as documented by regulatory authorities. The most frequently reported adverse event is diarrhea, which is categorized as Very Common (ge 1/10). Other common reactions (ge 1/100 to < 1/10) include nausea, vomiting, and mucocutaneous candidosis (thrush).


Adverse effects are documented across several System-Organ Classes, including Gastrointestinal Disorders, Nervous System Disorders (such as dizziness and headache, categorized as uncommon), and Hepatobiliary Disorders (e.g., elevations in liver enzymes, also uncommon).

Serious Adverse Reactions

Official labeling documents a range of serious reactions classified across several frequency bands, including those designated as Not Known (cannot be estimated). These include severe hypersensitivity reactions like anaphylaxis and severe skin conditions such as Stevens-Johnson syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Clinically important hepatitis and cholestatic jaundice are also documented, which may be severe.


Population and Exposure Safety Notes

Safety data notes specific patterns concerning certain populations and exposure duration. Hepatic events are reported predominantly in males and elderly patients and may be associated with prolonged treatment. Additionally, the risk of convulsions is noted in patients with impaired renal function. The medication is subject to safety restrictions, including a stated need for avoidance in cases of suspected infectious mononucleosis and a historical record of hepatic impairment associated with previous use of this drug.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation requires that immediate medical attention must be sought for any suspected overdose of Auger (Co-amoxiclav). Contacting a Poison Control Center or emergency services is the mandated action.

Overdose typically presents with gastrointestinal symptoms, including vomiting, diarrhea, and abdominal pain, often leading to fluid and electrolyte imbalance. However, more severe outcomes are documented.

Documented Severe Outcomes and Required Management

Severe Outcome Risk Population/Dose Considerations Officially Described Management
Amoxicillin trihydrate crystalluria (potential for acute renal failure) Higher risk in patients with impaired renal function or reduced urine output. Symptomatic and supportive treatment; Haemodialysis is documented as a measure to remove drug from circulation.
Convulsions (Central Nervous System effects) Associated with high doses and increased risk in patients with pre-existing impaired renal function. Close medical observation and hospital monitoring may be required.

No specific antidote is known for Auger overdose. The management strategy, as detailed in regulatory prescribing information, relies on supportive measures and observation to address the documented clinical manifestations and mitigate the risk of severe renal or neurological complications.

Therapeutic Uses of Auger

What Auger Treats: Main Uses and Benefits

Auger (Co-amoxiclav) is an antibiotic commonly used to manage bacterial infections. Its use is considered relevant in therapeutic contexts by supporting the management of the bacterial source and the corresponding resolution of clinical symptoms. This medication is utilized to address infections in the lungs, ears, sinuses, skin, and urinary tract, among other areas.


Key Therapeutic Focus

Auger is generally used across conditions characterized by periods of heightened symptoms of bacterial infection, especially where resistance to standard penicillins is anticipated. The medication helps address symptom clusters that may become intense or disruptive, such as productive cough, facial pressure, fever, localized pain, and swelling. Clinical scenarios where it is applied include treating severe acute bacterial rhinosinusitis, acute otitis media, cellulitis, dental abscesses, and infections following animal bites. Its use offers symptomatic relief that helps patients cope more steadily with the overall symptom burden associated with these illnesses.


Quick Fact: Symptom Management Domains

Quick Fact: Relief for Systemic Discomfort The medication supports the patient during episodes of heightened discomfort by addressing both localized and symptoms related to systemic imbalance, such as fever and general malaise. This contributes to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory labeling for Auger (Co-amoxiclav) strictly defines the populations who can and cannot use the medicine.

Populations for Whom Use is Contraindicated

Absolute prohibition applies to individuals with a history of:

  • Serious Hypersensitivity Reactions (e.g., anaphylaxis) to amoxicillin, clavulanic acid, any penicillin, or other beta-lactam antibacterial drugs.
  • Cholestatic Jaundice or Hepatic Dysfunction specifically associated with previous Co-amoxiclav use.

Age and Comorbidity Restrictions

Category Official Eligibility Rule
Age Groups Generally approved for adults and children ge 3 months (or ge 40 kg). Specific tablet forms are not recommended for children < 40 kg [Source 2.4].
Renal Function Use requires dose adjustment in severe renal impairment ( CrCl < 30 mL/min). Certain high-dose or extended-release formulations are contraindicated [Source 1.1].
Hepatic Function Use with caution is required, and hepatic function must be monitored in patients with liver impairment [Source 2.3].
Other Conditions Patients with or suspected of having Infectious Mononucleosis should avoid use [Source 1.2].
Pregnancy/Lactation Use is permitted only if clearly needed during pregnancy, and with caution during lactation [Source 3.4].

The eligibility profile is structured around these exclusions and conditions, ensuring that the medicine is only used when consistent with the labeled population safety criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several interaction patterns for Auger (Co-amoxiclav) based on pharmacokinetic and pharmacodynamic effects, establishing specific use constraints.

Documented Pharmacokinetic and Clearance Interactions

Co-administration with Probenecid is documented to result in an increase and prolongation of Amoxicillin's plasma concentration. This effect occurs because Probenecid inhibits the renal tubular secretion of Amoxicillin. Similarly, Auger is officially stated to reduce the renal clearance of Methotrexate, leading to an increase in Methotrexate exposure.

Pharmacodynamic Effects and Restrictions

Interaction with oral anticoagulants (such as Warfarin) is associated with reported instances of prolonged prothrombin time and an increased International Normalized Ratio (INR), reflecting an officially noted pharmacodynamic effect on coagulation status. Furthermore, the antibacterial component may significantly reduce the efficacy of the oral live typhoid vaccine (Ty21a). Due to this potential for efficacy loss, regulatory labeling mandates that the vaccine's administration must be postponed until at least 3 days after the completion of Auger treatment. Concurrent use of the Amoxicillin component with Allopurinol is noted to increase the likelihood of developing a skin rash.

Mechanism of Action

How Auger Works: Understanding its Mechanism of Action


Modulation of Receptor-Mediated Signaling

Auger acts within domains involving receptor-mediated signaling by initiating or suppressing specific signaling sequences. This modification of early molecular steps in the cascade modulates processes characterized by aberrant or excessive signaling, influencing the resulting physiological response profile.


Regulation of Key Pathway Activity

The compound engages mechanisms that influence aberrant or excessive signaling associated with heightened physiological responses. By targeting specific signaling patterns, Auger shifts the activity profile toward baseline parameters and decreases the magnitude of mediator-induced pathway activation.


Influence on Pathway Feedback Regulation

Auger is relevant in cascades where multiple layers of pathway activation occur, engaging mechanisms that influence feedback regulation within those pathways. This allows for modulation of specific pathway components, resulting in an altered systemic physiological output.

Dosage and Administration Information

How to Use Auger

The administration of Auger (Co-amoxiclav) is governed by standardized protocols detailing the route, schedule, and patient-specific requirements. The medicine is available for oral use, including tablets and suspensions, and for intravenous (IV) use, typically reserved for severe infections or for initiating treatment.

Oral administration occurs at the start of a meal to enhance the absorption of the clavulanic acid component and minimize potential gastrointestinal discomfort. Dosing typically follows a frequency of either twice daily (every 12 hours) or three times daily (every 8 hours), dependent upon the specific strength prescribed. For adults, standard doses may include 500 mg/125 mg or 875 mg/125 mg of the fixed combination.

Certain oral formulations, such as extended-release tablets, must be swallowed whole and must not be crushed or chewed. Pediatric dosing for patients weighing less than 40 kg is determined by the child’s body weight, calculated in mg/kg/day, and administered in divided doses.

The treatment course generally does not exceed 14 days without a physician review. Specific dosing adjustments are mandated for patients with renal impairment, where the total daily dose is reduced based on the patient's Creatinine Clearance (CrCl). For instance, patients with CrCl < 30 mL/min require a modification of the standard regimen. Older adults generally require no dosage adjustment unless underlying renal dysfunction is present. If a dose is missed, it is taken as soon as remembered, ensuring at least four hours pass before the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Auger (Co-amoxiclav)

The study landscape for Auger (Co-amoxiclav) in bacterial infections summarizes the official clinical research that was studied for Auger. It describes the types of research conducted, the focus of those studies, and the areas where evidence remains limited or where certainty is low.


Evidence for use in Respiratory and Sinus Infections

The study landscape for Auger in respiratory conditions includes various types of research, including short-term Randomized Controlled Trials (RCTs) and Observational Cohort Studies. This body of evidence was studied for conditions involving periods of heightened symptoms in the lungs and sinuses, with researchers primarily monitoring outcomes related to physical discomfort and measurements of clinical response.

Studies for Acute Bacterial Rhinosinusitis

Research focused on acute infections of the sinuses, often involving comparative trials where Auger was observed in adult and children alongside other antibiotics. These studies monitored outcomes related to patient-reported outcomes describing perceived discomfort and the clinical assessment of changes in symptoms over short, defined time intervals. What remains uncertain is whether the addition of the clavulanic acid component provides a definitive benefit in all cases of sinusitis where resistance to Amoxicillin alone is not typically suspected.

Studies for Community-Acquired Pneumonia

The evidence base for Community-Acquired Pneumonia (CAP) includes large observational studies that researched patterns of the drug's application. Research primarily examined severe clinical outcomes, such as measurements of 30-day mortality, alongside rates of achieving a pre-determined endpoint or failure rates. However, comparative evidence is lacking from large, recent, head-to-head RCTs against Amoxicillin alone across all severity levels.


Evidence for use in Ear, Skin, and Urinary Infections

Studies for Acute Otitis Media (AOM)

Research on middle ear infections was studied for pediatric patients, where clinical trials were used to evaluate outcomes describing episodic or acute changes related to conditions involving periods of heightened symptoms. Findings describe patterns observed in the studies where a defined proportion of children experienced a measured change in short-term outcomes related to physical discomfort. Certainty remains low regarding the specific added value of the combination over high-dose Amoxicillin monotherapy for all subgroups of children with AOM.

Studies for Skin and Soft Tissue Infections

Clinical studies for Skin and Soft Tissue Infections (SSTIs), such as cellulitis, often involve comparative trials designed to measure the rate of achieving a pre-defined clinical metric and the resolution of localized symptoms. The research evidence quality varies across studies due to the wide range of infection types grouped under the SSTI category.

Studies for Urinary Tract Infections (UTIs)

Research exploring Urinary Tract Infections (UTIs) includes smaller comparative trials and retrospective cohort studies, with a focus on recurrent or complicated infections. The comparative evidence is lacking in large, definitive trials for all uncomplicated UTIs.


What is Still Uncertain About Auger

The body of research highlights several areas where research is ongoing and where clarity is still needed:

  • The long-term effects are not fully established beyond the immediate post-treatment follow-up window.
  • Sample sizes were modest in some older trials, limiting the statistical ability to detect smaller differences in measured parameters.
  • Data for certain groups remain insufficient, particularly concerning the inclusion of pregnancy-related populations in efficacy trials.

Key Studies & References

  1. Amoxicillin and Clavulanate Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Auger (FAQ)


Q: What if I take Auger for longer than originally planned?

Regulatory documents specify that the treatment duration generally does not exceed 14 days and should not be prolonged without clinical re-evaluation. Taking the medicine for longer periods may be associated with the overgrowth of bacteria not susceptible to the drug. Regulatory safety notes also mention that liver-related events may be associated with prolonged treatment.


Q: Is Auger safe for children to take?

Official prescribing information indicates that this medicine is used for treating infections in children aged three months and older. Dosage recommendations for children are based on body weight, and certain formulations, such as specific tablets, are not recommended for those weighing less than 40 kilograms.


Q: Can older adults use Auger safely?

Official safety data notes that liver-related events have been reported predominantly in elderly patients. Generally, a dosage change is not required unless the patient has underlying kidney or liver issues that must be managed.


Q: Is Auger appropriate for use during pregnancy, according to official documents?

Regulatory documents categorize the medicine in Pregnancy Category B. Official information specifies that use during pregnancy is permitted only when the clinical need has been clearly established.


Q: What types of over-the-counter medicines might interact with Auger?

Regulatory information documents interactions with specific medicines, including Allopurinol and Probenecid. The official documentation also notes that the antibacterial component may reduce the effectiveness of the oral live typhoid vaccine (Ty21a).


Q: What is the risk of having an allergic reaction to Auger?

Official documentation describes the risk of serious hypersensitivity reactions, such as anaphylaxis and severe skin conditions like Stevens-Johnson syndrome (SJS). Severe reactions, if they occur, require urgent medical review and discontinuation of the medication.


Q: Is it necessary to have routine check-ups while taking Auger?

Official prescribing information indicates that close clinical monitoring is typically performed during the course of treatment. In patients taking oral anticoagulants, regular monitoring of INR (a measure of blood clotting) is required by regulatory labeling.


Q: Are there any foods or beverages that should be avoided when taking Auger?

The medicine is administered at the start of a meal for optimal absorption. Official labeling notes that the Amoxicillin component has no known interactions with foods or drinks that require them to be strictly avoided.


Q: Does Auger affect the ability to drive or operate machinery?

Official product characteristics documents review the medicine’s potential effects on the ability to drive and operate machinery. Since side effects like dizziness and headache are noted, the potential for these effects means that an individual's ability to drive or use machinery may be affected.


Q: Is there a large body of research supporting the use of Auger?

The regulatory approval of this combination product is supported by its extensive market experience and established medical literature. Official documents contain sections summarizing the evidence base across its approved uses, including studies for respiratory, ear, skin, and urinary infections.


Q: How common are serious adverse events with Auger?

Official documents classify the frequency of adverse effects, including serious ones. For many severe reactions, such as severe hypersensitivity or serious skin conditions, the frequency is categorized as 'Not Known.' This indicates that the true incidence cannot be reliably estimated from currently available data.


Q: Does using Auger require any specific monitoring of blood work?

Official documentation requires specific blood monitoring in certain situations. When used alongside oral anticoagulants, monitoring of INR (a measure of clotting) is required by regulatory documents. Additionally, patients with existing liver impairment may require baseline and regular liver function tests.


Q: What kind of studies led to the approval of Auger?

The regulatory approval of this combination product relied substantially on established medical literature and years of market experience. This approach, rather than solely using new original clinical studies, was the basis for the regulatory decision.


Q: Is Auger used to treat mental health issues?

According to official descriptions, the medicine is indicated only for treating infections caused by bacteria, specifically those affecting the ears, lungs, sinuses, skin, and urinary tract. Official labeling does not include any indications for the treatment of mental health issues.


Q: How long does the effect of a dose of Auger typically last?

Regulatory documents include pharmacokinetic data, such as the elimination half-life of the Amoxicillin component, which is approximately 1.0 to 1.3 hours. This metric describes how quickly the medicine is cleared from the body, not the clinical duration of action or how long symptoms are improved.


Q: Is Auger considered a narcotic or controlled substance?

Official drug status classifications indicate the medicine is a prescription-only product. It is not classified as a narcotic or controlled substance under the U.S. Controlled Substances Act (CSA) schedule.


Q: Can I drink alcohol while taking Auger?

Official information does not contain a specific warning against consuming alcohol with the medicine. However, official information notes that alcohol may worsen existing side effects like nausea or dizziness.


Q: Is it normal to feel [mild, non-specific side effect, e.g., tired] when starting Auger?

While official documents do not use the term 'normal when starting,' they document side effects by frequency. Dizziness and headache are listed as uncommon side effects. These reactions are known to occur but may not affect everyone who takes the medicine.


Q: Are there specific vitamins or supplements to avoid while taking Auger?

Official cautions indicate that there is not enough regulatory information to confirm that complementary medicines, vitamins, herbal remedies, and supplements are safe to take with this drug. This is because these products are typically not tested to the same regulatory standards as prescription medicines.


Q: Is Auger known to interact with birth control pills?

Official drug labels indicate that this medicine, like other broad-spectrum antibiotics, may reduce the effectiveness of oral contraceptives. This is thought to be due to effects on the intestinal flora.


Q: Does Auger change the way other medications are absorbed?

Official documents describe specific pharmacokinetic effects on other medications. For example, the medicine reduces the clearance of Methotrexate and affects the way Probenecid is handled by the body. This illustrates effects on how other drugs are eliminated.


Q: Is Auger used for pain management?

Official descriptions state the medicine's purpose is strictly to treat infections caused by bacteria. Pain relief or pain management is not listed as an approved use in official regulatory documents.


Q: Is it true that Auger can interfere with certain lab tests?

Official documentation confirms that the Amoxicillin component can interfere with certain lab tests. For instance, it may result in false-positive reactions when testing for urine glucose using non-enzymatic methods.


Q: What are the official guidelines regarding stopping the use of Auger?

Regulatory documents specify that the treatment duration generally does not exceed 14 days. Official safety notes indicate that immediate discontinuation is required if severe reactions, such as feverish generalized erythema associated with pustula (AGEP), occur.


Q: Does Auger interact with herbal products like St. John's Wort?

Official cautions indicate that there is not enough regulatory information available to confirm that herbal remedies are safe to take with this medicine. This is because these products are generally not subjected to the same standardized testing as prescription drugs.


Q: Can Auger affect sleep patterns?

Regulatory documentation lists trouble with sleeping as a rare side effect. Additionally, sleepiness is noted as a potential symptom of overdose.

How should Auger be stored and disposed of?

How to Store and Dispose of Auger (Amoxicillin and Clavulanate Potassium)

Official regulatory guidelines define specific storage requirements based on the medicine's form to ensure stability and safety.

Formulation Mandatory Storage Condition
Tablets Store at controlled room temperature (e.g., 20 C to 25 C), protected from light and moisture.
Reconstituted Suspension Must be refrigerated (2 C to 8 C) and must not be frozen.

Keep the medicine in its tightly closed original container and out of the sight and reach of children. The liquid suspension must be discarded after 7 to 10 days of refrigeration. Unused or expired medication must be disposed of via a medicine take-back program or other sanctioned methods; do not flush it down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Auger found in:

A-Z Index: